Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krishnendu Pal

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2007
Synthetic heterovalent inhibitors targeting recognition E3 components of the N-end rule pathwayMin Jae Lee, Krishnendu Pal, Takafumi Tasaki, et al.
Research Square|January 10, 2024
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic CatastropheHari K Rachamala, Vijay S Madamsetty, Ramcharan S Angom, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 22, 2018
VEGF receptor-1 modulates amyloid β 1-42 oligomer-induced senescence in brain endothelial cellsRamcharan Singh Angom, Ying Wang, Enfeng Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 5, 2024
Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastropheHari K Rachamala, Vijay S Madamsetty, Ramcharan S Angom, et al.
Oncogene|August 14, 2019
BRAF<sup>V600E</sup>-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenograftsDaofu Feng, Bo Qin, Krishnendu Pal, et al.
Nano Letters|October 5, 2011
Reactive oxygen species driven angiogenesis by inorganic nanorodsChitta Ranjan Patra, Jong-Ho Kim, Kallal Pramanik, et al.
Molecular Pharmaceutics|May 18, 2016
Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive TumorsSujan Kumar Mondal, Sudhakar Jinka, Krishnendu Pal, et al.
Nanoscale|October 10, 2017
Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancerKrishnendu Pal, Farah Al-Suraih, Roberto Gonzalez-Rodriguez, et al.
Oncotarget|November 22, 2017
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancerJair Machado Espindola-Netto, Claudia C S Chini, Mariana Tarragó, et al.
Molecular Cancer Therapeutics|December 12, 2013
Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancerKrishnendu Pal, Ying Cao, Irina N Gaisina, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2007
Synthetic heterovalent inhibitors targeting recognition E3 components of the N-end rule pathwayMin Jae Lee, Krishnendu Pal, Takafumi Tasaki, et al.
Research Square|January 10, 2024
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic CatastropheHari K Rachamala, Vijay S Madamsetty, Ramcharan S Angom, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 22, 2018
VEGF receptor-1 modulates amyloid β 1-42 oligomer-induced senescence in brain endothelial cellsRamcharan Singh Angom, Ying Wang, Enfeng Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 5, 2024
Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastropheHari K Rachamala, Vijay S Madamsetty, Ramcharan S Angom, et al.
Oncogene|August 14, 2019
BRAF<sup>V600E</sup>-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenograftsDaofu Feng, Bo Qin, Krishnendu Pal, et al.
Nano Letters|October 5, 2011
Reactive oxygen species driven angiogenesis by inorganic nanorodsChitta Ranjan Patra, Jong-Ho Kim, Kallal Pramanik, et al.
Molecular Pharmaceutics|May 18, 2016
Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive TumorsSujan Kumar Mondal, Sudhakar Jinka, Krishnendu Pal, et al.
Nanoscale|October 10, 2017
Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancerKrishnendu Pal, Farah Al-Suraih, Roberto Gonzalez-Rodriguez, et al.
Oncotarget|November 22, 2017
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancerJair Machado Espindola-Netto, Claudia C S Chini, Mariana Tarragó, et al.
Molecular Cancer Therapeutics|December 12, 2013
Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancerKrishnendu Pal, Ying Cao, Irina N Gaisina, et al.
Pageof 5